Response to anti-VEGF therapy in macular oedema secondary to acute retinal necrosis

A 55 year-old female patient with unilateral Acute Retinal Necrosis (ARN) developed macular oedema (MO) after the resolution of her necrosis. The macular oedema (MO) was managed and controlled for four years with intravitreal anti-VEGF injections. Anti-VEGF therapy could be useful for the treatment...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archivos de la Sociedad Española de Oftalmología (English ed.) 2019-01, Vol.94 (1), p.41-44
Hauptverfasser:	Sánchez Ramón, A, Piñón Mosquera, R, Mendieta Rasos, N
Format:	Artikel
Sprache:	eng ; spa
Schlagworte:	Acyclovir - therapeutic use Angiogenesis Inhibitors - therapeutic use Antiviral Agents - therapeutic use Female Humans Macular Edema - drug therapy Macular Edema - etiology Middle Aged Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retinal Necrosis Syndrome, Acute - complications Retinal Necrosis Syndrome, Acute - diagnostic imaging Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A 55 year-old female patient with unilateral Acute Retinal Necrosis (ARN) developed macular oedema (MO) after the resolution of her necrosis. The macular oedema (MO) was managed and controlled for four years with intravitreal anti-VEGF injections. Anti-VEGF therapy could be useful for the treatment of MO secondary to ARN, the same as for treating MO resulting from panuveitis, where its efficacy has been already demonstrated.
ISSN:	2173-5794
DOI:	10.1016/j.oftal.2018.07.007